Oracle's leading safety platform will help Voisin enhance compliance, mitigate risk, and expand global service offerings for its pharmaceutical clients
Voisin Consulting Life Sciences (VCLS), a well-established contract research organization (CRO) with a focus on unmet medical need and rare drug clinical trials, has chosen Oracle Argus to significantly enhance its global pharmacovigilance operations. By choosing Argus, VCLS will gain proven tools to enhance and deliver comprehensive, end-to-end pharmacovigilance services to its diverse global clientele.
"As a CRO deeply invested in specialized clinical trials, delivering cutting-edge and highly efficient pharmacovigilance services is fundamental to our success and the safety of our clients' patients," said Dr. Emmanuelle Voisin, founder and chief executive officer, VCLS. "Oracle Argus provides the advanced features, configurability, and reporting requirements we need to scale our operations, boost efficiency, and provide superior service to our expanding client roster."
VCLS chose Oracle Argus for its comprehensive capabilities, industry leadership, and proven track record. Oracle Argus solution will help VCLS strengthen its safety services and meet complex sponsor requirements to support a wide array of clients.
"With today's complex regulations, CROs need a dependable, advanced safety solution," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "This collaboration demonstrates Oracle's commitment to providing life sciences organizations with the safety technology required to accelerate drug development and support patient safety worldwide."
0 Comments